DaVita
DVA
$173.82
-0.81%
DaVita Inc. is a leading provider of kidney dialysis services, operating over 3,200 facilities worldwide and treating approximately 300,000 patients annually, with a dominant ~35% market share in the U.S. The company's revenue is heavily reliant on government payers, with about two-thirds of U.S. sales coming from Medicare and Medicaid, while commercial insurers, though only ~10% of patients, contribute nearly all profits. The current investor narrative centers on DaVita's strong operational performance and growth trajectory, highlighted by a 26.3% one-year stock price gain and a 51.8% year-to-date increase, despite recent volatility. The stock has attracted attention due to its robust earnings growth, strategic capital allocation, and the ongoing debate over healthcare policy impacts on dialysis reimbursement.…
DVA
DaVita
$173.82
Related headlines
Investment Opinion: Should I buy DVA Today?
Based on the analysis, DaVita is rated a 'Buy' with a thesis that its low valuation, steady revenue growth, and dominant market position offer an attractive risk/reward profile. The consensus analyst rating of 'Buy' with an average target price of $218.43 supports this view, implying a 25.7% upside from the current price of $173.82. The company's forward PE of 10.22x is below the industry average, and its PS ratio of 0.72x indicates the market is not fully pricing in its earnings potential.
Sign up to view all
DVA 12-Month Price Forecast
The AI assessment leans bullish due to DaVita's attractive valuation and consistent growth, but confidence is medium given the regulatory uncertainties and recent price volatility. The stock's low PE and strong cash flow generation provide a margin of safety, while the negative PEG ratio and high debt levels temper enthusiasm. If DaVita can maintain its growth trajectory and navigate policy changes, the stock has significant upside potential. However, any adverse regulatory development could quickly shift the stance to bearish, so monitoring policy news is crucial.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $218.43 and implied upside of +25.7% versus the current price.
Average Target
$218.43
0 analysts
Implied Upside
+25.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $270
Analyst target range
Analyst coverage is moderate with 7 analysts, and the consensus recommendation is 'Buy' with a mean rating of 2.375 (where 1 is Strong Buy and 5 is Sell). The average target price is $218.43, implying a 25.7% upside from the current price of $173.82. The target range is $165.00 to $270.00, with the low target suggesting a 5.1% downside and the high target implying a 55.3% upside. The wide spread between the low and high targets indicates significant uncertainty about the company's future performance, possibly due to regulatory risks or reimbursement changes. Recent ratings have been mostly neutral to positive, with UBS and Deutsche Bank maintaining Buy ratings, while Truist and Barclays hold Equal Weight/Hold, reflecting a cautiously optimistic outlook.
Drowning in data?
Find the real signal!
Bulls vs Bears: DVA Investment Factors
DaVita presents a compelling value opportunity with a low PE ratio, strong revenue growth, and a dominant market position, but it is weighed down by regulatory dependence, high leverage, and recent price volatility. The bull case is supported by solid fundamentals and analyst optimism, while the bear case highlights the fragility of its profit model and financial structure. Currently, the evidence slightly favors the bulls, as the valuation is attractive and growth is steady, but the key tension lies in whether regulatory and reimbursement risks will materialize, which could drastically alter the investment thesis. If DaVita can navigate policy changes and maintain its operational efficiency, the stock has significant upside; otherwise, the downside risks are substantial.
Bullish
- Strong Revenue Growth: DaVita's Q1 2026 revenue grew 5.96% YoY to $3.42 billion, continuing a stable upward trend from $3.38 billion in Q2 2025 and $3.42 billion in Q3 2025. This consistent growth reflects solid operational execution and increasing patient volumes.
- Attractive Valuation: With a trailing PE of 11.69x and forward PE of 10.22x, DaVita trades at a significant discount to the broader healthcare sector. The PS ratio of 0.72x further underscores undervaluation, suggesting the market is pricing in limited growth despite the company's stable earnings.
- Analyst Consensus Buy: The consensus recommendation is 'Buy' with a mean rating of 2.375 (1=Strong Buy, 5=Sell). The average analyst target price of $218.43 implies a 25.7% upside from the current price of $173.82, indicating that analysts see meaningful appreciation potential.
- Strong Profitability: Despite a slight dip in gross margin to 31.4% in Q1 2026, operating margin remains healthy at 14.1%, and net income of $197.5 million demonstrates consistent profitability. The company's ability to maintain double-digit operating margins supports its earnings power.
Bearish
- High Regulatory Risk: Approximately two-thirds of U.S. sales come from Medicare and Medicaid, making DaVita highly sensitive to government reimbursement policies. Any adverse changes in dialysis reimbursement rates could significantly impact revenue and profitability.
- Negative Equity and High Debt: DaVita has a negative debt-to-equity ratio of -23.12 and a negative ROE of -1.15, indicating a leveraged balance sheet with substantial debt. This financial structure increases vulnerability to interest rate hikes and economic downturns.
- Recent Price Volatility: The stock has experienced a -25.1% decline over the past month and a -12.4% decline over three months, reflecting significant volatility. The 52-week range of $101.00 to $247.49 shows that the stock can swing dramatically, posing risks for short-term investors.
- Dependence on Commercial Insurers: While commercial insurers represent only ~10% of U.S. patients, they contribute nearly all profits. Any shift in commercial payer mix or reimbursement negotiations could disproportionately impact earnings, creating concentration risk.
DVA Technical Analysis
DaVita's stock has been in a strong uptrend over the past year, with a 1-year price change of +26.3%, significantly outperforming the S&P 500's +20.5% over the same period. The current price of $173.82 sits at 70.2% of its 52-week range (between $101.00 low and $247.49 high), indicating the stock has pulled back from its highs but remains well above its lows. This positioning suggests the stock is in a corrective phase within a longer-term uptrend, offering a potential entry point for investors who believe the fundamental story remains intact.
Beta
0.87
0.87x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$101-$247
Price range past year
Annual Return
+26.3%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | -25.1% | +3.6% |
| 3m | -12.4% | +2.7% |
| 6m | +15.3% | +11.4% |
| 1y | +26.3% | +18.7% |
| ytd | +51.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
DaVita's revenue has been growing steadily, with the most recent quarter (Q1 2026) reporting $3.42 billion, a 5.96% year-over-year increase. This growth is consistent with the prior quarters: Q4 2025 revenue was $3.62 billion, Q3 2025 was $3.42 billion, and Q2 2025 was $3.38 billion, showing a stable growth trajectory. The company's net income for Q1 2026 was $197.5 million, with a net margin of 5.78%, which is lower than the 6.47% in Q4 2025 but higher than the 4.40% in Q3 2025, indicating some fluctuation but overall profitability. Gross margin for Q1 2026 was 31.4%, slightly down from 33.1% in Q2 2025, but the operating margin of 14.1% remains healthy, reflecting efficient cost management.
Quarterly Revenue
$3.4B
2026-03
Revenue YoY Growth
+6.0%
YoY Comparison
Gross Margin
31.4%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
Given DaVita's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 11.69x, while the forward PE is 10.22x, indicating that the market expects earnings growth. This is supported by the PEG ratio of -0.99, which is negative due to the negative earnings growth rate used in the calculation, but the forward PE suggests a reasonable valuation. Compared to the industry average, DaVita's PE is lower than the sector's typical multiple, suggesting the stock may be undervalued relative to its peers. Historically, DaVita's PE has ranged from 8.4x to 24.6x over the past few years, and the current trailing PE of 11.69x is near the lower end of that range, indicating potential value. The PS ratio of 0.72x is also low, further supporting the undervaluation thesis.
PE
11.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~19x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, DaVita carries a heavy debt load, evidenced by a negative debt-to-equity ratio of -23.12, which indicates that liabilities exceed shareholders' equity. This leverage amplifies the impact of rising interest rates, as interest expenses of $145 million in Q1 2026 consume a significant portion of operating income. The company's negative ROE of -1.15 further underscores the strain on equity holders, and while the current ratio of 1.29 provides some liquidity cushion, it is not robust. Additionally, revenue concentration in government payers (two-thirds of U.S. sales) creates cash flow volatility tied to policy decisions, and the recent dip in gross margin to 31.4% suggests potential cost pressures that could erode profitability if not managed.
FAQ
The key risks include regulatory changes to Medicare and Medicaid reimbursement, which account for two-thirds of U.S. sales and could significantly impact revenue. Financial risks stem from high debt levels, as indicated by a negative debt-to-equity ratio of -23.12, which could strain cash flow if interest rates rise. Market risks include competitive pressures from other dialysis providers and potential loss of commercial payer contracts, which are crucial for profitability. Additionally, the stock's recent volatility, with a -25.1% one-month decline, highlights the potential for significant price swings.
The 12-month forecast for DaVita is cautiously optimistic, with a base case probability of 50% targeting a price range of $190-$220, aligning with the analyst average target of $218.43. The bull case, with a 30% probability, could see the stock reach $270, while the bear case, with a 20% probability, could see it fall to $165 or lower. The most likely scenario is the base case, assuming steady growth and no major regulatory shocks. Investors should monitor earnings and policy developments to adjust their expectations.
DaVita appears undervalued based on its trailing PE of 11.69x and forward PE of 10.22x, which are lower than the sector average. The PS ratio of 0.72x also indicates that the market is not paying a premium for its revenue. Historically, the PE has ranged from 8.4x to 24.6x, and the current level is near the lower end, suggesting the stock is trading at a discount. This valuation implies that the market is pricing in limited growth or higher risks, but if DaVita delivers on its growth potential, the stock could re-rate higher.
DaVita is a good buy for investors seeking a value opportunity in healthcare, given its low PE of 11.69x and forward PE of 10.22x, which are below industry averages. The analyst consensus is 'Buy' with an average target price of $218.43, implying a 25.7% upside from the current price of $173.82. However, the stock carries significant regulatory and leverage risks, so it is best suited for those with a higher risk tolerance and a long-term perspective. If you believe DaVita can maintain its growth and navigate policy changes, the risk/reward is favorable; otherwise, consider waiting for more clarity.
DaVita is better suited for long-term investment due to its stable business model, dominant market position, and attractive valuation. The stock's beta of 0.87 indicates lower volatility than the market, but recent price swings suggest short-term trading carries significant risk. The company's consistent revenue growth and cash flow generation support a long-term holding period of at least 3-5 years, allowing investors to ride out regulatory and market fluctuations. For short-term traders, the stock's volatility could offer opportunities, but it requires active monitoring and risk management.
